COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02959606
Recruitment Status : Unknown
Verified July 2017 by Seung-Kee Min, Seoul National University Hospital.
Recruitment status was:  Recruiting
First Posted : November 9, 2016
Last Update Posted : July 27, 2017
Information provided by (Responsible Party):
Seung-Kee Min, Seoul National University Hospital

Brief Summary:
After endovascular treatment (EVT) for peripheral artery disease (PAD), dual antiplatelet therapy (DAAT) of aspirin (ASA) and clopidogrel are currently drug of choice to prevent occlusion. Anplone SR®, controlled-released Sarpogrelate hydrochloride, has been introduced as an anti-platelet agent for the drug of PAD. The aim of this study was to compare the efficacy and safety of Anplone + aspirin and clopidogrel + aspirin in patients who underwent EVT for femoro-popliteal occlusive disease.

Condition or disease Intervention/treatment Phase
Peripheral Arterial Disease Drug: Sarpogrelate SR 300mg Drug: Clopidogrel Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 272 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial
Study Start Date : December 2016
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : January 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Sarpogrelate SR 300mg + ASA

Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.

Other Name: Anplone SR

Drug: Sarpogrelate SR 300mg
Other Name: Anplone SR

Active Comparator: Clopidogrel + ASA

Clopidogrel is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.

Other Name: Plavix

Drug: Clopidogrel

Primary Outcome Measures :
  1. Restenosis rate (50%>) in 6 months by CT angiography [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Target lesion restenosis(TLR) in 6 months [ Time Frame: 6 months ]
  2. Major bleeding complication [ Time Frame: 6 months ]
  3. Ipsilateral major amputation [ Time Frame: 6 months ]
  4. All-cause mortality [ Time Frame: 6 months ]
  5. All adverse events [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Adult, >18 years old
  2. Angiographically-confirmed significant femoro-popliteal (FP) stenosis or occlusion by atherosclerosis
  3. Successful FP intervention; residual stenosis <30%
  4. Without significant residual inflow disease; Intact iliac artery inflow (with or without intervention of iliac or below knee arteries)
  5. patent outflow status; at least 1 arterial runoff in below knee arteries
  6. All kind of fem-pop intervention including POBA, stent, DCB, DES for TASC A~ D

Exclusion Criteria:

  1. At risk of hemorrhage, bleeding tendency or thrombophilia
  2. Acute limb ischemia / inflammatory arterial disease
  3. Contraindication or allergic to ASA, clopidogrel, Anplone
  4. Medication of warfarin
  5. Pregnancy, hepatic dysfunction, thrombocytopenia
  6. Previous FP bypass or intervention
  7. Impossible to stop clopidogrel before EVT

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02959606

Layout table for location contacts
Contact: Seung-Kee Min, MD.PhD. +82.2-2072-0297

Layout table for location information
Korea, Republic of
Seung-Kee Min, Recruiting
Seoul, Korea, Republic of, 110-744
Contact: Seung-Kee Min, MD.    +82.2-2072-0297   
Sponsors and Collaborators
Seoul National University Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Seung-Kee Min, Professor, Seoul National University Hospital Identifier: NCT02959606    
Other Study ID Numbers: SAFE
First Posted: November 9, 2016    Key Record Dates
Last Update Posted: July 27, 2017
Last Verified: July 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Peripheral Vascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Fibrinolytic Agents
Fibrin Modulating Agents
Serotonin Antagonists
Serotonin Agents